

# Press Release

Regulated information

## DISCLOSURE OF RECEIVED NOTIFICATION

Waregem (Belgium) / Rotterdam (Netherlands)<sup>1</sup>, 31 March 2014 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV received notifications on 27 March 2014 and on 28 March 2014 from JP Morgan Asset Management UK Ltd. concerning the acquisition or disposal of voting securities. On 27 March the shareholding of JP Morgan Asset Management UK Ltd. has fallen below the disclosure threshold of 3% through the disposal of voting securities and on 28 March the shareholding crossed the disclosure threshold of 3% through the acquisition of voting securities.

Based on the denominator of 31,358,358 (total number of voting rights) and the relevant notifications that Arseus received, the shareholder structure as of 31 March 2014 is as follows:

	Number of shares	% of effective voting rights
EnHold NV	8,166,908	26.04%
Alychlo NV / Coucke	653,376	2.08%
BNP Paribas Investment Partners SA	1,609,182	5.13%
JP Morgan Asset Management UK Ltd.	946,804	3.02%
Arseus NV (treasury shares)	881,378	2.81%
Public	19,100,710	60.92%
<b>Total</b>	<b>31,358,358</b>	<b>100.00%</b>

The original notification forms are available at [www.arseus.com](http://www.arseus.com).

*In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.*

### For more information:

Marieke Palstra  
Director Investor Relations  
+31 88 33 11 213 (Office)  
[marieke.palstra@arseus.com](mailto:marieke.palstra@arseus.com)

---

<sup>1</sup> This press release was sent out by Arseus NV and Arseus BV.

## **Arseus profile**

Arseus is a R&D scientific company delivering innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into three divisions: Fagron is global market leader in pharmaceutical compounding. Corilus develops and supplies unique integrated ICT solutions with substantial added value to medical specialists and is market leader in Belgium, France and the Netherlands. HL Technology develops and produces innovative healthcare devices for the dental and medical markets. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.